Cognitive dysfunction in multiple sclerosis: Current approaches to clinical management

Expert Review of Neurotherapeutics

Volumn 2, Issue 5, 2002, Pages 731-742

  Amato, Maria Pia ^a   Zipoli, Valentina ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Cognitive dysfunction; Cognitive rehabilitation; Multiple sclerosis pharmacotherapy

Indexed keywords

4 AMINOPYRIDINE; AMANTADINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BETA1A INTERFERON; CYCLOSPORIN; DONEPEZIL; GLATIRAMER; GLUCOSE; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INTERFERON BETA SERINE; METHOTREXATE; MITOXANTRONE; NICOTINIC ACID; PEMOLINE;

AMNESIA; ART THERAPY; CLINICAL TRIAL; COGNITIVE DEFECT; COGNITIVE THERAPY; COUNSELING; DISABILITY; DRUG EFFICACY; EXERCISE; FATIGUE; GROUP THERAPY; HUMAN; IMAGERY; INTELLIGENCE; MEDITATION; MINI MENTAL STATE EXAMINATION; MULTIPLE SCLEROSIS; MUSIC THERAPY; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PSYCHOTHERAPY; QUALITY OF LIFE; RATING SCALE; RELAXATION TRAINING; REVIEW; SYMPTOMATOLOGY;

EID: 0036042672     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.2.5.731     Document Type: Review

References (78)

1. The story of Multiple Sclerosis
2. What is new in the treatment of multiple sclerosis?
3. Neuropsychological aspects of multiple sclerosis
4. Cognitive dysfunction in MS II: Impact on employment and social functioning
5. Demographic, clinical and cognitive characteristics of MS patients who continue to work
6. Cognitive impairment in early-onset multiple sclerosis: Pattern, predictors and impact on everyday life in a 4-year follow-up
7. Multiple sclerosis: A preliminary study of selected variables affecting rehabilitation outcome
8. Memory deficits and early cognitive deterioration in multiple sclerosis
9. Cognitive dysfunction in early-onset multiple sclerosis. A reappraisal after 10 years
10. Metamemory in MS
11. Language functions in patients with multiple sclerosis
12. Language functions in incipient cognitive decline in multiple sclerosis
13. Neuropsychological test performance as a function of the duration of MS-related symptomatology
14. Disability and intellectual function in multiple sclerosis
15. Chronic progressive multiple sclerosis: Relationship between cerebral ventricular size and neuropsychological impairment
16. Neuropsychological findings in relapsing-remitting and chronic-progressive multiple sclerosis
17. Memory disturbance in chronic-progressive multiple sclerosis
18. Memory impairment in multiple sclerosis: A quantitative review
19. Clinically isolated lesions of the type seen in multiple sclerosis: A cognitive, psychiatric and MRI follow-up study
20. A serial study of psychometric and magnetic resonance imaging changes in multiple sclerosis
21. Cognitive function in recent-onset demyelinating diseases
22. Deficient learning and memory in early and middle phases of multiple sclerosis
23. The prevalence of cognitive impairment in a community survey of multiple sclerosis
24. Rating neurological impairment in multiple sclerosis: An expanded disability status scale (EDSS)
25. Quantification of impairment in MS: Discussion of the scales in use
26. Patterns of cognitive impairment in relapsing-remitting and chronic-progressive multiple sclerosis
27. Influence of clinical variables on neuropsychological performance in multiple sclerosis
28. Patterns of cognitive impairment in secondary progressive stable phase of multiple sclerosis: Correlations with MRI findings
29. 18F-fluorodeoxyglucose positron emission tomography study
30. Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis
31. Magnetic resonance imaging correlates of neuropsychological impairment analysis in multiple sclerosis
32. Relation between MR abnormalities and patterns of cognitive impairment in multiple sclerosis
33. Serial neuropsychological assessment and magnetic resonance imaging analysis in multiple sclerosis
34. Neuropsychological assessment in multiple sclerosis: A follow-up study with magnetic resonance imaging
35. Brain magnetic resonance imaging correlates of cognitive impairment in multiple sclerosis
36. Cognitive function in primary progressive and transitional progressive multiple sclerosis: A controlled study with MRI correlates
37. Ventricular size, cognitive function and depression in patients with multiple sclerosis
38. Neuropsychological assessment in patients with relapsing-remitting multiple sclerosis and mild functional impairment: Correlation with magnetic resonance imaging
39. Neuropsychological assessment in MS: Clinical, neurophysiological and neuroradiological relationships
40. Neuropsychological and structural brain lesions in multiple sclerosis: A regional analysis
41. White matter lesions and cognitive deficits: Relevance of lesion pattern?
42. Isolated U-fiber involvement in MS: Preliminary observations
43. Correlates of executive function in multiple sclerosis: The use of magnetic resonance spectroscopy as an index of focal pathology
44. Changes in the normal appearing brain tissue and cognitive impairment in multiple sclerosis
45. 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician
46. Screening for cognitive impairment in multiple sclerosis: An evaluation of the Mimi-Mental State Examination
47. The sensivity of the Mini-Mental State Exam in the white matter dementia of multiple sclerosis
48. Identifying multiple sclerosis patients with mild or global cognitive impairment using the Screening Examination for Cognitive Impairment (SEFCI)
49. Comparison of two brief neuropsychological batteries in people with multiple sclerosis
50. Three screening batteries to detect cognitive impairment in multiple sclerosis
51. Screening for cognitive dysfunction in multiple sclerosis
52. Guidelines for neuropsychological research in multiple sclerosis
53. Efficacy and toxicity of cyclosporin in chronic progressive multiple sclerosis: A randomized, double-blinded, placebo-controlled clinical trial
54. Treatment of multiple sclerosis with methtrexate
55. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial
56. Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b
57. Co-polymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a Phase III multicenter, double-blind placebo-controlled trial
58. Neuropsychologic status in multiple sclerosis after treatment with glatiramer
59. Neuropsychological assessment in multiple sclerosis: A follow-up study with magnetic resonance imaging
60. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis
61. Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis
62. Amantadine treatment of fatigue associated with multiple sclerosis
63. The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis
64. The effects of 4-aminopyridine on cognitive function in patients with multiple sclerosis: A pilot study
65. Fatigue in progressive multiple sclerosis: Results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine
66. Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: Results of a randomized, double-blind, placebo-controlled, crossover trial
67. A 12-week, open trial of donepezil hydrochloride in patients with multiple sclerosis and associated cognitive impairments
68. Multiple sclerosis: Empirical literature for the clinical health psychologist
69. Teaching memory strategies to persons with multiple sclerosis
70. The role of executive function in imagery mnemonics: Evidence from multiple sclerosis
71. The psychosocial impact of multiple sclerosis: Exploring the patient's perspective
72. Neuropsychology and multiple sclerosis: Diagnostic and rehabilitative approaches
73. Effects of neuropsychological treatment in patients with multiple sclerosis
74. Computer assisted retraining of attentional impairments in patients with multiple sclerosis
75. Cognitive therapy for multiple asclerosis: A preliminary study
76. Neuropsychological counseling improves social behavior in cognitively-impaired multiple sclerosis patients
77. Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: A two centre Phase 2 study